Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects

N/ACompletedNCT00206791

Biomatlante3 enrolled

Overview

The purpose of this non-comparative study is to test, for the first time, the bioactivity of a new "ready to use" calcium phosphate biomaterial in fillings of little losses of osseous substance from various origins, such as traumatic and benign tumoral causes.

A lot of osseous substitution products were already used to fill osseous defects in order to prevent losses of osseous that are envisaged and so prejudicial. Synthetic calcium phosphate ceramics (particularly granulated forms) already has shown their osteoconduction potential in human at different sites. But it is difficult to put these granules in very little place. The injectable form of calcium phosphate granules "ready to use" is easier to be used and allow a diminution of the risk of infection during surgery, and permit homogeneity of the biomaterial. Injectable form of calcium phosphate granules did already has shown his biocompatibility and biofunctionality in animals. The purpose of this study is to study the biocompatibility and biofunctionality of this biomaterial in his injectable form in fillings of little losses of osseous substance from various origins were no charge will act to the biomaterial.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Grafting, Bone

Interventions

MBCP-Gel (tm)DEVICE

MBCPGel 5ml

MBCP GelDEVICE

MBCPGel 5ML

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Medium osseous defects (inferior to 20 cc) without articular communication * Patients without a personal medical history of bone infection, cancer, diabetes, tuberculosis, and in general, any pathology which could interfere with the results of the study or expose the patient to additional risk * Patients without drepanocytosis, or congenital or acquired immunizing deficit * Patients who have the benefit of a social security system, a previous medical exam and who were informed and gave free consent about this study Exclusion Criteria: * Proven nicotinism and alcoholism * Pregnant or nursing women * Patients who received another study drug or another study device in the past 3 months or patients who will be included in another clinical study * If postoperative follow-up for a patient is considered to be random by the investigator, he/she should not be included

Locations (4)

CHU de Bordeaux - Hôpital PELLEGRIN -Service d'Orthopédie - Traumatologie C

Bordeaux, France

CH des Broussailes - Service de Chirurgie Orthopédique et Traumatologique

Cannes, France

CHU de Fort de France - Hôpital Pierre ZODBA-QUITMAN - Service d'Orthopédie et Traumatologie

Fort de France, France

Service de Chirurgie Orthopédique et Traumatologique - CHU de la Pitié Salpétrière

Paris, France

Outcomes

Primary Outcomes

Presence or absence of an edging to radiolucent on the radiographic stereotypes between the biomaterial and the osseous walls of the osseous defect at different times (3, 6 and 12 months after surgery)

Time frame: 3, 6 and 12 months

Secondary Outcomes

An analysis of numeric radiographic stereotypes by grey steps will study the evolution of the density of the implant and environmental bone.

Time frame: 3, 6 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.